Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension  

Oleh:

Archer, Stephen L. ; Michelakis, Evangelos D.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 361 no. 19 (Nov. 2009), page 1864-1871.
Topik: Phosphodiesterase Type 5 Inhibitors; Pulmonary Arterial Hypertension

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2009.06 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Pulmonary arterial hypertension, a disease of the pulmonary vasculature, is diagnosed when there is both an increased mean pulmonary-artery pressure (>25 mm Hg at rest or 30 mm Hg with exercise) and a pulmonary-capillary wedge pressure of less than 15 mm Hg. The diagnosis also requires that secondary pulmonary hypertension due to lung disease, hypoxia, thromboembolism, and left ventricular muscle or valve disease be ruled out. 1 Pulmonary arterial hypertension occurs in a rare idiopathic form (in which 10% of cases are familial) but is more commonly associated with other conditions, including connective-tissue diseases, congenital heart disease, portopulmonary disease, and human immunodeficiency virus (HIV) infection1 or the use of anorexigens (see the Table in the Supplementary Appendix, available with the full text of this article at NEJM.org). The functional classification system of the New York Heart Association has been adapted by the World Health Organization (WHO) for use in classifying symptoms in patients with pulmonary hypertension

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali